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BACKGROUND. In health, inflammation resolution is an active process governed by specialized 
proresolving mediators and receptors. ALX/FPR2 receptors (ALX) are targeted by both proresolving 
and proinflammatory ligands for opposing signaling events, suggesting pivotal roles for ALX in the 
fate of inflammatory responses. Here, we determined if ALX expression and ligands were linked to 
severe asthma (SA).
METHODS. ALX expression and levels of proresolving ligands (lipoxin A4 [LXA4], 15-epi-LXA4, and 
annexin A1 [ANXA1]), and a proinflammatory ligand (serum amyloid A [SAA]) were measured in 
bronchoscopy samples collected in Severe Asthma Research Program-3 (SA [n = 69], non-SA [NSA, 
n = 51] or healthy donors [HDs, n = 47]).
RESULTS. Bronchoalveolar lavage (BAL) fluid LXA4 and 15-epi-LXA4 were decreased and SAA was 
increased in SA relative to NSA. BAL macrophage ALX expression was increased in SA. Subjects 
with LXA4
loSAAhi levels had increased BAL neutrophils, more asthma symptoms, lower lung 
function, increased relative risk for asthma exacerbation, sinusitis, and gastroesophageal reflux 
disease, and were assigned more frequently to SA clinical clusters. SAA and aliquots of LXA4
loSAAhi 
BAL fluid induced IL-8 production by lung epithelial cells expressing ALX receptors, which was 
inhibited by coincubation with 15-epi-LXA4.
CONCLUSIONS. Together, these findings have established an association between select ALX 
receptor ligands and asthma severity that define a potentially new biochemical endotype for 
asthma and support a pivotal functional role for ALX signaling in the fate of lung inflammation.
TRIAL REGISTRATION. Severe Asthma Research Program-3 (SARP-3; ClinicalTrials.gov 
NCT01606826)
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Introduction
Asthma is the most common disease of  chronic lung inflammation, affecting nearly 1 in 13 Americans (1). 
The current clinical criteria for the diagnosis of  asthma include a broad spectrum of  patients with hetero-
geneous disease processes and distinct responses to medications (2). Approximately 10%–15% of  asthmatic 
patients have severe asthma (SA) with daily symptoms and inadequate asthma control despite asthma-tar-
geted controller medication use. These patients with SA have increased morbidity with significant adverse 
outcomes, including frequent outpatient visits, admissions to the hospital, and even life-threatening exac-
erbations (3). Cluster analyses utilizing patient clinical characteristics have identified at least 5 distinct 
clusters of  asthmatic individuals (4, 5). Identifying disease mechanisms in asthma pathogenesis is critical 
to move the field from clinical phenotyping to molecular endotyping of  patients to enable precision medi-
cine approaches for improved asthma management (6). While type 2 “high” inflammation accounts for 
approximately 50% of  asthma pathobiology (7), disease mechanisms for the remaining 50% of  asthmatic 
subjects remain to be determined. A more detailed understanding of  mechanisms underlying non–type 2 
inflammation in asthma is needed.
In health, the resolution of  inflammation is an active process governed by specific cellular events reg-
ulated by specialized proresolving mediators (SPMs) derived from essential fatty acids (8). Lipoxin A4 
(LXA4) and 15-epi-LXA4 are endogenous arachidonic acid–derived SPMs that potently regulate acute 
inflammation, yet are underproduced in many inflammatory diseases, including SA (9). Lipoxins and their 
stable analogs are protective in murine models of  allergic lung inflammation, and display cell type–specific 
actions for human leukocytes to inhibit proinflammatory IL-13 production by group 2 innate lymphoid 
cells, halt granulocyte trafficking and activation, decrease T cell cytokine production, enhance natural killer 
cell functions, and stimulate macrophage CD206 expression and efferocytosis to resolve tissue inflamma-
tion (reviewed in ref. 9). Lipoxins also inhibit leukotriene-mediated prophlogistic actions, including in vivo 
in asthma (10), and decrease cytokine-induced human airway contractile responses (11). In peripheral 
blood, exhaled breath condensates, sputum, and bronchoalveolar lavage (BAL) fluid (BALF), LXA4 lev-
els are decreased in SA relative to non-SA (NSA) (12–15), suggesting a link between defective resolution 
mechanisms and persistent airway inflammation in some asthma patients.
LXA4 and 15-epi-LXA4 interact with specific receptors to exert their proresolving actions. Their high-
affinity cognate receptors are ALX/FPR2 receptors (ALX) with a KD of  approximately 1 nM (16). Of  
interest, ALX was the first receptor described to engage both lipid and peptide ligands (16), and subse-
quently several lipid and peptide ligands for ALX have been identified. Ligand recognition sites differ 
in the extracellular domains of  ALX receptors and trigger distinct downstream events that dramatically 
change the signaling properties of  the receptor depending on the engaging ligand (17). In sharp contrast 
to LXA4’s counter-regulatory signaling, SAA engages the same ALX receptors to promote inflammation 
(18, 19). SAA is generated as an acute-phase protein in COPD exacerbations in amounts that are 2–3 log 
orders higher than LXA4 that overwhelms SPM signaling via ALX (18). Another ALX ligand of  potential 
interest in SA is annexin A1 (ANXA1), a corticosteroid-inducible protein that can interact with ALX 
receptors to transduce proresolving actions similar to LXA4 (20). Of  interest, when apparently healthy 
individuals are challenged with a skin irritant, they segregate into fast and slow resolvers of  the dermal 
wound based on lipoxin production and expression of  ALX receptors (21). Thus, relative levels of  these 
lipid and peptide ALX ligands could serve as a rheostat for inflammatory host responses in airway disease, 
as lipoxins can allosterically inhibit SAA interactions with ALX (18). Together, the relative abundance 
and actions of  these proinflammatory versus proresolving ALX ligands may biochemically regulate air-
way phlogistic tone and contribute to unresolved inflammation in SA.
Here, we analyzed BALF samples collected from subjects participating in the National Heart, Lung 
and Blood Institute’s Severe Asthma Research Program-3 (SARP-3) and have identified a potentially new 
asthma biochemical endotype related to levels of  the ALX receptor ligands LXA4 and SAA that was associ-
ated with neutrophilic inflammation, increased asthma symptoms, and decreased lung function in SA.
FUNDING SOURCES. National Heart, Lung and Blood Institute, the NIH, and the German Society 
of Pediatric Pneumology.
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Results
Subject characteristics. Subjects with SA and NSA, and nonasthmatic healthy donors (HD) were recruited 
to participate in SARP-3 at 7 research centers across the United States. Relative to NSA, subjects with SA 
had increased symptoms as manifested by lower Asthma Control Test (ACT) and higher Asthma Control 
Questionnaire (ACQ) scores. Spirometric measures of  lung function were lower in SA than NSA and HD 
despite the SA cohort’s use of  more asthma-targeted medications (Table 1). A subset of  subjects agreed to 
bronchoscopy with BAL as part of  their baseline phenotyping. SA subjects had more lung inflammation 
with increased BAL neutrophils (Table 1).
SA subjects have decreased lipoxins and increased SAA and macrophage ALX receptor expression. The fate of  
innate inflammatory responses is dictated in part by ALX receptor signaling (16, 21), so the presence of  
BALF ALX ligands with proinflammatory (i.e., SAA) or proresolving properties (i.e., LXA4, 15-epi-LXA4, 
and ANXA1) and BAL cell surface ALX receptor expression were determined. SA subjects had significant-
ly less BALF LXA4 (median 0.23 pg/μg protein, mean 0.28 pg/μg protein) and 15-epi-LXA4 (median 1.02 
pg/μg protein, mean 1.24 pg/μg protein) than NSA subjects (LXA4: median 0.32 pg/μg protein, mean 0.40 
pg/μg protein; 15-epi-LXA4: median 1.47 pg/μg protein, mean 1.88 pg/μg protein) (Figure 1, A and B). 
Table 1. Clinical characteristics and bronchoalveolar lavage leukocytes for subjects undergoing bronchoscopyA
Healthy Donors (HD) Nonsevere Asthma (NSA) Severe Asthma (SA) NSA vs. SA HD vs. NSA HD vs. SA 
No. of subjects 47 51 69
Clinical data
Age 40.1 ± 12.9 (20–62) 36.9 ± 12.4 (18–61) 42.4 ± 13.6 (14–67) ns ns ns
% Male 19 (40%) 17 (33%) 24 (35%) ns ns ns
% African American 11 (23%) 14 (27%) 22 (32%) ns ns ns
% White 31 (66%) 37 (74%) 45 (65%) ns ns ns
BMI 27.6 ± 5.7 (20–44) 30.0 ± 9.2 (18–61) 31.4 ± 8.2 (19–67) ns ns C
Symptom control
% UncontrolledB n.a. 32 (63%) 68 (98%) D
ACQ n.a. 1.08 ± 0.9 (0–3) 1.93 ± 1.1 (0–5) D
ACT n.a. 19.61 ± 4.0 (7–25) 14.48 ± 4.5 (5–23) D
Lung function
FEV1 % predicted 102.4 ± 12.5 (78.46–139.2) 89.8 ± 16.3 (42–124) 75.0 ± 19.1 (35–116) D E D
FVC % predicted 104.7 ± 14.2 (84.12–137.2) 102.6 ± 17.2 (64–145) 89.4 ± 17.6 (52–133) D ns D
FEV1/FVC 97.7 ± 5.6 (85.4–109.6) 87.5 ± 9.0 (61–109) 82.8 ± 9.0 (62–106) C D D
Medications
Inhaled corticosteroids 0 (0%) 35 (69%) 67 (97%) D
High dose of inhaled 
corticosteroids
0 (0%) 4 (8%) 66 (96%) D
Oral steroids 0 (0%) 0 (0%) 16 (23%) D
Long-acting β agonists 0 (0%) 21 (37%) 64 (93%) D
Long-acting anticholinergic 
medication
0 (0%) 0 (0%) 3 (4%) P = 0.13
Leukotriene receptor 
antagonists 
0 (0%) 11 (22%) 24 (35%) P = 0.12
Omalizumab 0 (0%) 1 (2%) 8 (13%) C
BAL leukocyte differentials
Total cell count (millions) 4.9 ± 4.6 (0–25) 4.0 ± 2.7 (0–12) 6.4  ± 13.2 (0–107) ns ns ns
Macrophages (%) 91.7 ± 5.8 (73–99) 92.2 ± 5.1 (79–99) 87.7 ± 10.1 (53–99) E ns C
Neutrophils (%) 1.6 ± 1.9 (0–10) 1.4 ± 1.4 (0–7) 3.3 ± 4.9 (0–24) E ns C
Eosinophils (%) 0.3 ± 0.4 (0–2) 1.1 ± 2.8 (0–17) 1.8 ± 5.0 (0–35) ns ns ns
Lymphocytes (%) 6.5 ± 5.0 (0–22) 5.3 ± 4.5 (0–19) 7.3 ± 5.9 (0–34) ns ns ns
AValues represent the mean ± SD (range). BUncontrolled symptoms were defined as the occurrence of one of the following: 2 or more steroid bursts, 
hospitalization, intensive care unit admission, use of a ventilator, FEV1 % predicted less than 80%, ACT less than 20, or self-reported worsening with 
tapering steroids. BMI, body mass index; ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; FEV1, forced expiratory volume in 1 second; FVC, 
forced vital capacity; n.a., not applicable. CP < 0.05, DP < 0.001, EP < 0.01, ns = not significant. Comparison between 3 groups was performed by 1-way 
ANOVA followed by Tukey’s test to adjust for multiple comparisons and χ2 test. Comparison between 2 groups was performed by Student’s t test.
 
4insight.jci.org   https://doi.org/10.1172/jci.insight.93534
C L I N I C A L  M E D I C I N E
BALF lipoxins were significantly increased in NSA relative to HD, without significant differences between 
SA and HD cohorts (Figure 1, A and B), consistent with the findings in an earlier SARP cohort (14). No 
significant differences in immunoreactive ANXA1 levels were identified between the cohorts (Figure 1C). 
In contrast, SAA levels were increased in SA (median 3.03 pg/μg protein, mean 11.35 pg/μg protein) 
relative to NSA (median 0 pg/μg protein, mean 11.21 pg/μg protein) (Figure 1D). Of  note, BALF SAA 
levels were below the limit of  detection in 51 of  the 120 asthma subjects and these samples were arbitrarily 
assigned a value of  0 pg/μg protein for analysis. Differences in BALF ALX ligand levels were also present 
when BALF was not corrected for protein (Supplemental Figure 1; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.93534DS1). BAL macrophage surface ALX receptor 
expression was determined by flow cytometry, with data expressed as a normalized index for ALX (medi-
an fluorescence intensity [MFI] of  ALX divided by MFI of  isotype control) (see Methods). A stepwise 
increase in the BAL macrophage ALX index from HD to NSA to SA was detected (Figure 1E).
ALX ligands differentially correlate with asthma inflammation, symptoms, and lung function. To screen for 
relationships between the BALF ALX ligand levels and asthma clinical parameters, a Pearson correlation 
matrix was constructed using measures of  disease activity from all asthma subjects (NSA and SA; n = 
120) (Figure 2). LXA4 levels correlated positively with 15-epi-LXA4 and inversely with SAA. The ALX 
ligands were also compared to clinical parameters of  lung inflammation, asthma symptoms, and measures 
of  lung function. Notably, the percentage of  BALF neutrophils was inversely correlated with LXA4 and 
15-epi-LXA4 and positively correlated with SAA. As expected, the ACQ and ACT scores were inversely 
correlated and significantly related to lung function. BALF levels of  LXA4 were inversely correlated with 
asthma symptoms (i.e., high ACQ, low ACT scores). LXA4 and 15-epi-LXA4 were also positively associat-
ed with lung function. SAA was not significantly related to asthma symptoms or lung function parameters. 
There were no significant correlations between BALF ALX ligand levels and fractional exhaled nitric oxide 
(FeNO), methacholine PC 20 (provocation challenge causing a 20% fall in forced expiratory volume in 1 
second [FEV1]), or lung function reversibility with albuterol. Because of  limited sample size, this analysis 
was not corrected for multiple comparison testing, yet it strongly suggested relationships between select 
ALX ligands and major characteristics of  clinical asthma, namely lung inflammation, asthma symptoms, 
and lung function.
BAL neutrophilia in SA is associated with decreased LXA4 and increased SAA levels. BAL leukocyte subsets were 
determined in NSA and SA subjects and HD. As expected, macrophages were the most numerous BAL cell 
type accounting for 88%–92% of BAL leukocytes (Figure 3A). SA subjects had significantly higher percent-
ages of  BAL neutrophils than NSA subjects (mean ± SEM 3.32% ± 0.59% SA versus 1.38% ± 0.19% NSA; 
Figure 3B). There were also trends for increased BAL lymphocytes and eosinophils in SA relative to NSA and 
Figure 1. Relative abundance of BALF ALX ligands and ALX receptor expression differs in asthma. BALF was obtained from subjects with asthma (n 
= 120) and healthy donors (n = 47, gray circles). Asthmatic subjects were assigned to NSA (n = 51, blue squares) and SA (n = 69, red triangles) cohorts by 
SARP criteria. (A) LXA4 and (B) 15-epi-LXA4 were extracted from BALF and quantified by ELISA (see Methods). (C) ANXA1 and (D) SAA levels were deter-
mined by ELISA. Scatter plots show individual data points for each subject normalized to protein levels with the median value noted by the horizontal 
line. (E) Flow cytometry was performed on viable BAL macrophages in n = 32 HD, n = 33 NSA, and n = 38 SA subjects to measure surface ALX expression. 
Data are expressed as the ALX index (MFI ALX divided by MFI isotype control). *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001 by Kruskal-Wallis test, 
followed by Dunn’s test for multiple comparisons. BALF, bronchoalveolar lavage fluid; ALX, airway lipoxin A4 receptor; HD, healthy donors; NSA, non-
severe asthma; SA, severe asthma; SARP, Severe Asthma Research Program; LXA4, lipoxin A4; 15-epi-LXA4, 15-epimer lipoxin A4; ELISA, enzyme-linked 
immunosorbent assay; ANXA1, annexin A1; SAA, serum amyloid A; MFI, median fluorescence intensity.
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HD (Figure 3, C and D). BALF LXA4 levels inversely correlated with 
BAL neutrophil percentage in the total asthma cohort or when the SA 
cohort was analyzed independently (Figure 3, E and F). In contrast, 
SAA levels were positively correlated with BAL neutrophil percent-
age in the complete asthma cohort as well as when SA was analyzed 
separately (Figure 3, G and H). LXA4 levels were also positively cor-
related with lung function (i.e., FEV1 and forced vital capacity [FVC] 
[percentage predicted values]), but there was no correlation between 
SAA levels and lung function in this cohort (Supplemental Figure 2).
ALX receptor ligands and expression are associated with asthma symptoms. To further investigate relation-
ships between the ALX signaling pathway and measures of  asthma symptoms, the continuous variables for 
BAL ALX ligands were converted to categorical high and low subgroups using the median value to define 
a cutoff  between the subgroups. Using the median BALF SAA value (1.22 pg/μg protein; Figure 4A), the 
relationships between SAAhi and SAAlo subjects and measures of  asthma symptoms were determined. 
Subjects defined as SAAhi had significantly increased ACQ and decreased ACT scores relative to SAAlo 
subjects (Figure 4B), consistent with increased asthma symptoms in the SAAhi group. When stratified by 
asthma severity, there were more NSA subjects that were SAAlo and more SA subjects that were SAAhi (Fig-
ure 4C). ACQ scores were significantly different between SAAlo and SAAhi subjects when considering only 
those subjects with SA (Figure 4D). Of  note, significant differences between the SAAhi and SAAlo cohorts 
for ACQ and ACT scores were not apparent in the NSA cohort (Supplemental Figure 3A).
Because BALF LXA4 levels were inversely related to SAA levels and asthma symptoms by Pearson 
correlation (Figure 2), the difference between LXA4
hi and LXA4
lo groups of  subjects and asthma symp-
toms was determined. The median LXA4 level was used as a cutoff  between groups (0.23 pg/μg protein; 
Figure 4E). LXA4
lo subjects had higher ACQ scores and significantly lower ACT scores compared with 
LXA4
hi subjects, consistent with more symptoms in the LXA4
lo group (Figure 4F). When stratified by 
severity, NSA subjects were more numerous in the LXA4
hi group and approximately 70% of  the LXA4
lo 
cohort were subjects with SA (Figure 4G). In contrast to our findings with SAA, the low LXA4 levels 
were not significantly related to symptom scores in the SA cohort (Figure 4H); however, among NSA 
subjects, the LXA4
hi group did have significantly fewer symptoms as evidenced by higher ACT scores 
(Supplemental Figure 3B). Of  note, administration of  a single dose of  intramuscular triamcinolone did 
not result in discernible changes in either LXA4 or SAA levels after 3 to 6 weeks in either SA or NSA 
subjects (Supplemental Figure 4).
With opposing relationships for asthma symptoms for the ALX ligands SAA and LXA4, we next per-
formed similar analyses for the BAL macrophage ALX index. Asthma subjects were categorized into ALXhi 
and ALXlo cohorts using the median ALX index to define the cutoff  between subgroups (median 4.61; Fig-
ure 4I). ALXhi asthma subjects had higher ACQ scores and significantly lower ACT scores, consistent with 
increased asthma symptoms (Figure 4J). After stratification by asthma severity (Figure 4K), ALXhi subjects 
had significantly increased symptoms by both measures (i.e., ACQ and ACT) in the SA cohort (Figure 4L). 
The ALX index was not significantly linked to symptom score in the NSA cohort (Supplemental Figure 
3C). Of  added interest, the BAL macrophage ALX index correlated with macrophage indices of  MHC 
class 2 and CD206 expression in asthma subjects (Supplemental Figure 5).
Figure 2. Relationship between ALX ligands, lung inflammation, asthma 
symptoms, and lung function in asthma. The relationships between BALF 
ALX ligand levels, BAL leukocytes, asthma symptom score, and measures of 
lung function, were determined by Pearson correlation matrix (see Methods) 
for n = 51 NSA and n = 69 SA subjects. Positive correlations are noted in 
blue and negative correlations in red. The color intensity is proportional 
to Pearson’s correlation coefficient, with deeper colors denoting stronger 
associations. *P < 0.05, **P < 0.01 by Pearson correlation analysis. BALF, 
bronchoalveolar lavage fluid; ALX, airway lipoxin A4 receptor; NSA, nonse-
vere asthma; SA, severe asthma; LXA4, lipoxin A4; 15-epi-LXA4, 15-epimer 
lipoxin A4; ANXA1, annexin A1; SAA, serum amyloid A; ACQ, Asthma Control 
Questionnaire; ACT, Asthma Control Test; FEV1, forced expiratory volume in 
1 second; FVC, forced vital capacity; FeNO, fractional exhaled nitric oxide; PC 
20, provocation challenge causing a 20% fall in FEV1.
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SAA and LXA4 levels together represent a biochemical endotype that distinguishes SA from NSA. Individually, 
SAA and LXA4 levels were both associated with asthma severity. More SA subjects had SAA
hi and LXA4
lo 
levels and more NSA subjects had SAAlo and LXA4
hi levels (Figure 4). In SA, macrophage ALX expression 
was increased (Figure 1) and associated with increased asthma symptoms (Figure 4), so we next determined 
if  BALF levels for the combination of  the ALX ligands was linked to SA. Asthma subjects were divided 
into 4 groups based on BALF LXA4 and SAA levels (Figure 5A). The approach of  categorical grouping 
of  high and low (based on median values) was chosen because the relationship between an individual’s 
BALF LXA4 and SAA levels suggested that these ALX ligands were independently regulated (Figure 5A). 
When subjects were stratified by clinical severity, it was striking that more than half  of  NSA but fewer than 
a quarter of  SA were LXA4
hiSAAlo (beige, Figure 5B). In contrast, 41% of  SA subjects were LXA4
loSAAhi 
compared with 22% of  NSA subjects (purple, Figure 5B). Of note, for asthmatic subjects, the relative ratio 
of  BALF SAA to LXA4 levels was strongly correlated with BAL neutrophilia (Figure 5C), more so than the 
level of  either ALX ligand independently (Figure 3, E and G). When comparing asthmatic subjects in these 
2 distinct groups, the LXA4
loSAAhi group had significantly higher BAL neutrophils and asthma symptoms 
(i.e., higher ACQ, lower ACT) and lower lung function (i.e., percentage predicted FEV1 and FVC) than the 
LXA4
hiSAAlo group (Figure 5, D–F). The total BAL white blood cell count and percentage of  lymphocytes 
and eosinophils did not differ between the 2 groups (Supplemental Figure 6, A–C). The percentage of  sub-
jects with an ACQ score greater than 1.5 was higher in the LXA4
loSAAhi cohort (Supplemental Figure 6D), 
representing another measure of  the increased symptoms in this group.
Cluster analyses from SARP-1 used clinical parameters to identify 5 asthma subtypes (mild allergic 
asthma, mild-moderate allergic asthma, more severe older-onset asthma, severe variable allergic asthma, 
and severe fixed-airflow asthma) (5). Using this classification here with SAA and LXA4 as biochemical 
markers of  ALX receptor signaling, it was notable that 71% of  the LXA4
hiSAAlo group were assigned to 
one of  the NSA clusters and 64% of  the LXA4
loSAAhi subjects were assigned to one of  the SA clusters 
(Figure 5G and Supplemental Figure 6E).
Figure 3. BAL neutrophils are increased in severe asthma and differentially related to BALF LXA4 and SAA levels. BAL samples were obtained from NSA 
and SA subjects and leukocyte subsets were enumerated. (A) Pie charts express the mean percentage of BAL neutrophils, lymphocytes, eosinophils, and mac-
rophages in n = 47 HD, n = 51 NSA, and n = 69 SA subjects. (B–D) Scatter plots show individual subject data points with mean ± SEM for BAL (B) neutrophils, 
(C) lymphocytes, and (D) eosinophils in the HD (gray circles), NSA (blue squares), and SA (red triangles) cohorts. *P < 0.05, **P < 0.01 by 1-way ANOVA. (E and 
F) The relationship between BALF neutrophils and LXA4 was determined for (E) all asthma subjects and (F) for the SA cohort only. (G and H) The relation-
ship between BALF neutrophils and SAA was determined for (G) all asthma subjects and (H) for the SA cohort only. SAA levels that were undetectable were 
assigned a value of 0 pg/μg protein and were included in the correlation analysis. Pearson correlation r value and significance are noted and regression lines 
are shown. BALF, bronchoalveolar lavage fluid; HD, healthy donors; NSA, nonsevere asthma; SA, severe asthma; LXA4, lipoxin A4; SAA, serum amyloid A.
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SAA is an acute-phase protein, and with the relationship for the LXA4
loSAAhi endotype to asthma 
severity and neutrophilic lung inflammation, we next determined if  there was a relationship for LXA4 
and SAA to exacerbations and common asthma comorbidities. Both high SAA and low LXA4 levels were 
significantly related to sinusitis, gastroesophageal reflux disease (GERD), and obesity (BMI > 30), and 
low LXA4 was also related to history of  more frequent acute exacerbation over the prior year (Table 2). 
Together, the combination of  low LXA4 levels and high SAA levels (i.e., the LXA4
loSAAhi endotype) was 
even more closely associated with these asthma comorbidities (Table 2).
SAA and 15-epi-LXA4 signaling via ALX receptors regulates production of  the neutrophil chemoattractant IL-8. 
To determine the functional relationship for these ALX receptor ligands, we next turned to an ALX-depen-
dent in vitro reporter assay that we have previously qualified in chronic obstructive pulmonary disease 
(18). A549 lung epithelial cells were stably transfected to express the human ALX/FPR2 receptor (hALX). 
BALF samples were selected from HD, NSA, and SA subjects with representative levels of  ALX ligands 
(Figure 6A). SAA gave a concentration-dependent (0–10 ng/ml) increase in IL-8 production by A549hALX 
cells (Figure 6B). When the A549hALX cells were exposed to BALF (see Methods), several of  the representa-
tive SA BALFs substantially increased IL-8 production (Figure 6C), reflective of  the relative amounts of  
BALF SAA and LXA4. The addition of  exogenous 15-epi-LXA4 inhibited A549
hALX cell IL-8 production by 
cells conditioned with BALF (Figure 6D). Of  note, maximal inhibition of  IL-8 production by 15-epi-LXA4 
was for A549hALX cells that had been conditioned with BALF from LXA4
loSAAhi subjects (Figure 6D).
Discussion
Here, in SARP-3, we measured the abundance of  4 ligands for ALX receptors, namely LXA4, 15-epi-
LXA4, ANXA1, and SAA, with the potential for opposing effects on asthmatic airway responses. In SA, 
BAL macrophage ALX receptor expression was increased and BALF ligands for ALX were selectively 
regulated. BALF levels of  proresolving lipoxins were decreased and levels of  proinflammatory SAA were 
increased in SA. Levels of  lipoxins inversely correlated to SAA, BAL neutrophils, and asthma symptoms, 
and lipoxins were positively correlated to measures of  lung function. SAAhi and ALXhi subjects more com-
monly had SA with increased ACQ and decreased ACT scores. When LXA4 and SAA levels were consid-
ered together in a combined endotype, a stronger association with asthma symptoms, lung function, and 
airway neutrophilia was noted than when either mediator was considered individually. LXA4
loSAAhi sub-




hiSAAlo subjects segregated to SA and NSA clinical clusters, respectively. 
Importantly, LXA4
loSAAhi subjects had significantly increased likelihood for asthma exacerbation in the 
past year and for the asthma comorbidities of  sinusitis, GERD, and obesity. Exposure to SAA or BALF 
from SA subjects increased production of  the neutrophil chemoattractant IL-8 by ALX-expressing human 
Table 2. Asthma exacerbations and comorbidities are associated with high SAA and low LXA4A
SAAlo (n = 60) SAAhi (n = 60) P value (χ2) P value (χ2 with Bonferroni correction)
>1 AE 21 (35%) 24 (40%) ns ns
Sinusitis 12 (20%) 24 (40%) 0.01 0.04
GERD 18 (30%) 28 (47%) 0.04 ns
BMI > 30 19 (32%) 32 (53%) 0.01 0.04
LXA4lo (n = 60) LXA4hi (n = 60)
>1 AE 29 (48%) 16 (27%) 0.01 0.04
Sinusitis 24 (40%) 12 (20%) 0.02 ns
GERD 29 (48%) 17 (28%) 0.01 0.04
BMI > 30 34 (57%) 17 (28%) 0.002 0.008
SAAloLXA4hi (n = 40) SAA
hiLXA4lo (n = 39)
>1 AE 10 (25%) 18 (46%) <0.05 ns
Sinusitis 6 (15%) 18 (46%) 0.003 0.01
GERD 11 (28%) 22 (56%) 0.009 0.04
BMI > 30 11 (41%) 26 (74%) <0.001 <0.005
AResults are expressed as number of patients (percentage). SAA, serum amyloid A; LXA4, lipoxin A4; AE, acute exacerbation; GERD, gastroesophageal 
reflux; BMI, body mass index; ns, not significant
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lung epithelial cells in vitro. This SAA-driven IL-8 production by epithelial cells was mitigated by exposure 
to 15-epi-LXA4 at pharmacological doses, supporting a functional interaction between the ALX ligands rel-
evant to the neutrophilic inflammation in SA. Together, these findings support a mechanistic role for ALX 
receptor signaling by SAA and LXA4 in lung inflammation in SA that defines a potentially new biochemi-
cal endotype for patient stratification in asthma.
ALX receptors are intriguing targets for regulating the fate of  inflammatory responses. LXA4 and SAA 
interact with ALX receptors to exert opposing effects on inflammation (18). ALX receptors are 7-mem-
brane-spanning, G protein–coupled receptors that are present on several lung cell types relevant to asthma 
pathogenesis, including neutrophils (22), eosinophils (23), group 2 innate lymphoid cells (24), natural killer 
cells (24), lymphocytes (25), monocytes (26), dendritic cells (27, 28), macrophages (29), and airway struc-
tural cells (30). LXA4 is a high-affinity ligand for ALX that signals for antiinflammatory and proresolving 
cellular responses (16). SAA binds with lower affinity, yet this acute-phase reactant is substantially more 
abundant than LXA4 during infection and the upstroke of  acute inflammation (18). Also relevant in SA 
patients with comorbidities, corticosteroids can enhance SAA production, especially in conjunction with 
Figure 4. SAA and macrophage ALX expression are associated with increased symptoms in severe asthma. Asthma subjects were categorized into 
subgroups based on low or high BALF levels of SAA (A–D), LXA4 (E–H), and macrophage ALX expression (I–L). The median value for each variable was 
used to define the cutoff between the low and high subgroups (SAA cutoff = 1.22 pg/μg protein, LXA4 cutoff = 0.25 pg/μg protein, ALX index cutoff = 
4.6 pg/μg protein). Cutoff values are delineated by the gray vertical line. A histogram shows the distribution of subjects based on BALF (A) SAA level, (E) 
LXA4 level, and (I) BAL macrophage ALX index. (B, F, and J) Validated measures of asthma symptoms (ACQ and ACT scores) were compared between low 
(open diamonds) and high (closed diamonds) subgroups for SAA, LXA4, and ALX index. (C, G, and K) The distributions of SAA, LXA4, and ALX index among 
NSA (blue) and SA (red) subjects are shown in violin plots. (D, H, and L) ACQ and ACT scores were compared in SA subjects for low (open triangles) and 
high (closed triangles) subgroups for SAA, LXA4,  and ALX index. Scatter plots show individual subject data with mean ± SEM. n = 51 NSA and n = 69 SA 
subjects.*P < 0.05, **P < 0.01 by Mann-Whitney test or 2-tailed Student’s t test. BALF, bronchoalveolar lavage fluid; SAA, serum amyloid A; ACQ, asthma 
control questionnaire; ACT, asthma control test; NSA, nonsevere asthma; SA, severe asthma; LXA4, lipoxin A4; ALX, airway lipoxin A4 receptor.
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LPS (18). Distinct from LXA4’s interaction with the seventh transmembrane domain and adjacent regions 
(31, 32), SAA interacts with the first and second extracellular loop domains (33), resulting in a marked shift 
in receptor conformation and dimerization that changes the receptor’s proresolving signaling to proinflam-
matory signaling (17). Here in SA, ALX expression was increased on BAL macrophages and associated 
with increased asthma symptoms. Macrophage ALX expression correlated with surface CD206 expression, 
which marks M2 macrophages that participate in endogenous pathways of  inflammation resolution (34, 
35). Together with the increased SAA and decreased lipoxins in SA BALF, the increase in ALX expression 
on BAL macrophages likely reflects SAA-driven outcomes, including the increased lung inflammation (i.e., 
BAL neutrophilia) despite higher doses of  corticosteroids. With the presence of  SAA and LXA4 in proxim-
ity to ALX receptors in the lung and their divergent influences on inflammatory responses, ALX receptors 
are poised to serve as a pivotal signaling nexus for acute inflammation or its resolution.
Lipoxins are products of  arachidonic acid metabolism that are structurally and functionally distinct 
from leukotrienes and prostaglandins. LXA4 was first detected in humans in BALF from patients with lung 
disease, including asthma (36). Lipoxins are the lead members of  a new genus of  endogenous chemical 
Figure 5. BALF SAA and LXA4 levels are distinct in clinically severe and nonsevere asthma. (A) The number and percentages of asthma subjects with 
BALF levels of LXA4 and SAA that were below (low) or above (high) the median value were identified and subjects were grouped into 4 phenotypes based 
on LXA4 and SAA levels. Noted are subjects in the LXA4
hiSAAlo group (beige quadrant) and LXA4
loSAAhi group (purple quadrant). The relationship between 
individual subject levels of LXA4 and SAA was determined for all asthma subjects. (B) The 4 groups of subjects based on BALF SAA and LXA4 low and 
high cohorts were determined for subjects and stratified by asthma severity; NSA (left), SA (right). (C) The relationship between the SAA/LXA4 ratio and 
BAL neutrophils (%) was determined in n = 120 asthma subjects. Pearson correlation r value and significance are noted and regression line is shown. (D–F) 
Scatter plots show comparisons of subjects in the LXA4
hiSAAlo group (beige) to subjects in the LXA4
loSAAhi group (purple) for measures of (D) inflammation 
(BALF neutrophils [%]), (E) asthma symptoms (ACQ and ACT scores), and (F) lung function (percentage predicted FEV1 and FVC). (G) Subjects in the  
LXA4
hiSAAlo and LXA4
loSAAhi groups were assigned to clinical clusters as defined in SARP-1 (5) and the percentage of subjects assigned to NSA and SA 
clusters is indicated. n = 51 NSA and n = 69 SA subjects.*P < 0.05, **P < 0.01 by 2-tailed Student’s t test. BALF, bronchoalveolar lavage fluid; LXA4, lipoxin 
A4; SAA, serum amyloid A; NSA, nonsevere asthma; SA, severe asthma; ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; FEV1, forced expi-
ratory volume in 1 second; FVC, forced vital capacity; SARP, Severe Asthma Research Program.
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signals, SPMs, which are partially defined by their ability to inhibit granulocyte recruitment and activa-
tion in inflamed tissues as well as to promote macrophage-mediated clearance of  dead cells, microbes, 
and debris in catabasis (8). Distinct from increased leukotriene production by some asthmatic patients, 
lipoxin levels are decreased in uncontrolled asthma and SA (13). Current anti-leukotriene drugs would not 
be expected to increase lipoxins in asthma. There are likely multiple factors responsible for the defective 
lipoxin production in SA; however, the increased oxidative stress in SA airways was recently determined 
to be a major cause of  reduced lipoxin generation (11). In human studies, inhaled LXA4 dampens bron-
choprovocation in asthma (10) and lipoxins regulate cytokine-mediated increases in bronchial constriction 
induced by methacholine, histamine, and thromboxane (11). Recently, a stable LXA4 analog was shown 
to markedly decrease allergic inflammation and symptoms in patients with juvenile eczema (37). Preclini-
cal studies have established that LXA4 analogs that resist metabolic inactivation can prevent and potently 
reduce allergen-driven airway hyperresponsiveness to methacholine, airway mucus metaplasia, and type 
2 inflammation (38, 39). Transgenic expression of  hALX receptors also leads to decreased inflammatory 
responses to allergens, supporting a role for endogenous ALX ligands in antiinflammation and proresolu-
tion (23). In addition to ALX, lipoxins can interact with additional receptors, including cysLT1 — the 
pharmacological target of  one of  the classes of  anti-leukotriene drugs (40). Together, these findings point 
to pivotal proresolving roles for lipoxins in health to control airway phlogistic responses and promote their 
resolution. Here, the diminished BALF levels of  lipoxins in SA would be predicted from prior publica-
tions to disable a major endogenous regulatory pathway for airway inflammation, mucus, and hyperre-
activity, and our results show a strong and consistent correlation between low LXA4 and increased lung 
inflammation, asthma symptoms, and comorbidities, and lower lung function in SA.
In contrast to lipoxins, there are several peptide ligands for ALX receptors that engage these receptors 
to promote inflammatory responses. The acute-phase reactant SAA is one of  the ALX peptide ligands and 
can induce neutrophil chemotaxis and activation via ALX (41, 42). SAA is increased in severe allergic 
asthma (43) and can prevent dendritic cell apoptosis to induce glucocorticoid resistance in CD4+ T cells 
(44). Here, BALF SAA levels were increased in SA and strongly associated with BAL neutrophils. SAAhi 
subjects had increased asthma symptoms and a higher relative risk of  sinusitis, GERD, and obesity. If  
subjects had both low LXA4 levels and high SAA levels (i.e., LXA4
loSAAhi) then their relative risk for BAL 
neutrophils, asthma symptoms, and lower lung function were all increased. Recently, some subjects with 
SA with non–type 2 inflammation were identified as IL-6hi (45). IL-6 induces SAA expression (46) and may 
Figure 6. SAA and 15-epi-LXA4 signaling via ALX receptors regulates production of the neutrophil chemoattractant IL-8. A549 human epithelial cells 
expressing human ALX receptors (A549hALX) were exposed to BALF from HD, NSA, or SA subjects (24 hours, 37°C, 5% CO2) and IL-8 levels were measured 
in the cell-free supernatant by ELISA (see Methods). (A) Mean levels of LXA4, 15-epi-LXA4, and SAA in BALF from n = 15 subjects used for A549hALX cell 
incubations are shown in stacked bar graphs and the relative proportions are noted in pie charts. (B) IL-8 production by A549hALX cells was measured after 
incubation with saline control or SAA (2.5 ng/ml or 10 ng/ml) for 24 hours. (C) IL-8 production by A549hALX cells was measured after 24 hours of exposure 
to BALF from HD (n = 3), NSA (n = 6), or SA (n = 5) and is expressed as an increase relative to saline controls. Incubations with BALF without an increase 
in IL-8 production relative to saline control were assigned a value of zero. (D) A549hALX epithelial cells were exposed to BALF from subjects with endog-
enous levels that were LXA4
hiSAAlo (n = 5) or LXA4
loSAAhi (n = 6) followed by exposure to exogenous 15-epi-LXA4 (100 nM). Percentage inhibition of IL-8 
production after 15-epi-LXA4 exposure was calculated. *P < 0.05, ****P < 0.001 by (B) 1-way ANOVA, (C) Kruskal-Wallis test, and (D) Mann-Whitney test. 
ALX, airway lipoxin A4 receptor; LXA4, lipoxin A4; 15-epi-LXA4, 15-epimer lipoxin A4; SAA, serum amyloid A; HD, healthy donors; NSA, nonsevere asthma; 
SA, severe asthma; IL-8, interleukin-8; BALF, bronchoalveolar lavage fluid.
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conspire with this acute-phase protein to activate neutrophils and non–type 2 lung inflammation in SA, in 
particular in those with systemic metabolic alterations associated with obesity. In A549hALX epithelial cells, 
BALF from LXA4
loSAAhi subjects increased production of  the neutrophil chemoattractant IL-8, which 
was inhibitable by 15-epi-LXA4. At ALX receptors, 15-epi-LXA4 inhibition of  SAA is allosteric in nature 
(18), and when given at pharmacological doses, 15-epi-LXA4 can decrease SAA-driven IL-8 production by 
human airway epithelial cells in vitro and SAA-mediated acute inflammation in vivo in mice (18). Of  inter-
est for SA, SAA production is increased by corticosteroids and its expression is synergistically increased by 
the combination of  steroids and LPS (18). Additional soluble mediators acting via distinct or synergistic 
pathways with SAA also are likely to contribute to epithelial cell IL-8 production and neutrophil chemoat-
traction in SA. Subjects enrolled in SARP-3 were clinically characterized before and after intramuscular 
triamcinolone and adult subjects with SA continued to manifest lower FEV1 and worse asthma control as 
compared with NSA after the systemic corticosteroids (47). Of  note, BALF levels of  LXA4, 15-epi LXA4, 
and SAA were not significantly altered by a single dose of  intramuscular triamcinolone when measured 3 
to 6 weeks after steroid administration. Unlike 15-epi-LXA4, corticosteroids do not inhibit SAA-mediated 
lung inflammation (18), suggesting that for some subjects with SA their chronic neutrophilic lung inflam-
mation could be perpetuated by corticosteroids and that SAA levels could inform more precise asthma 
management by helping to identify subjects at risk for this unintended consequence of  corticosteroids.
Biochemical analyses here have linked ALX receptor signaling to the pathophysiology of  SA. Using 
clinical and statistical approaches, 5 phenotypes of  adult asthma have been defined (5), but there remains 
a need to connect these phenotypes to distinct molecular mechanisms for SA pathogenesis (6). We chose 
a candidate pathway approach based on preclinical evidence that linked ALX signaling to SA, and BAL 
LXA4 and SAA levels segregated subjects into discrete clinical clusters, suggesting that this biochemical 
pathway could convey additional value for patient stratification as an asthma endotype. Findings here 
suggest that these ALX ligands should be included in future studies designed to comprehensively model 
genetic, metabolic, and environmental influences and clinical characteristics for patient endotyping in SA.
Here, we have identified significant associations for BALF LXA4
loSAAhi levels with neutrophilic lung 
inflammation and poorly controlled asthma; however, there are several potential limitations to consider. 
While it was advantageous for biochemical analyses to have a relatively large number of  BAL samples from 
this carefully phenotyped group of  asthma subjects, it would not be practical to routinely perform bron-
choscopy in a clinical (or clinical trial) setting. It will be important in future studies to obtain and analyze 
respiratory samples collected by less invasive means (i.e., sputum, exhaled breath condensate) to determine 
the influence of  anatomic compartment on the relationships uncovered here with bronchoscopy specimens. 
The cross-sectional nature of  the analyses here does not address the stability of  this endotype, a ques-
tion best addressed with samples obtained by less invasive means. Regarding additional ALX ligands, the 
ELISA used here for ANXA1 does not distinguish between intact and cleaved protein, so the absence of  a 
relationship here does not preclude its potential existence when more specific experimental tools become 
available. There are also several additional peptide and lipid ligands for ALX receptors that might further 
enhance the discriminatory power of  ALX signaling for identification of  asthma endotypes.
In summary, ALX receptor expression was increased in asthmatic BAL macrophages and we have iden-
tified a cassette of  ALX receptor ligands that are selectively regulated in BALF in asthma. Levels of  lipox-
ins and SAA correlated with lung inflammation and clinical parameters of  asthma control. In particular, 
subjects with LXA4
loSAAhi BALF were more likely to have SA with increased BAL neutrophils, asthma 
symptoms, and asthma comorbidities, and decreased lung function. At pharmacological levels, 15-epi-LXA4 
functionally opposed SAA signaling at ALX receptors to inhibit production of  the neutrophil chemoattrac-
tant IL-8. BALF LXA4
loSAAhi subjects were assigned to discrete clinical clusters from LXA4
hiSAAlo subjects, 
suggesting that these biochemical mediators could identify subgroups of  asthma subjects and serve as a new 
asthma biochemical endotype for non–type 2, steroid resistant inflammation in SA.
Methods
Study design. SARP-3 is an NHLBI-funded study designed to characterize molecular, cellular, and physi-
ological phenotypes in subjects with SA and NSA (ClinicalTrials.gov NCT01606826). Asthmatic and 
healthy subjects were recruited and completed baseline characterization with some subjects agreeing to 
bronchoscopy. Details regarding SARP methods, subject enrollment, and study procedures can be found 
in Peters et al. (45).
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Participants and sample collection. Subjects 13 years of  age and older with asthma and healthy control 
subjects were recruited between November 2012 and February 2015 by 7 geographically dispersed research 
centers in the USA. European Respiratory Society/American Thoracic Society guidelines were used to 
categorize subjects as SA or NSA (48). Control subjects were individuals who reported general health and 
were nonsmokers with no history of  lung disease, atopic disease, or allergic rhinitis. BAL was performed 
with three 50-ml aliquots of  warm saline, and BALF was recovered by hand suction. Subjects received 
intramuscular triamcinolone (1 mg/kg up to a maximum dose of  40 mg) and some subjects agreed to 
undergo a second bronchoscopy 3 to 6 weeks later and BAL samples were collected in the same manner. 
BAL cells were enumerated and differential leukocyte counts determined. Cell-free BALF supernatant was 
divided into several aliquots. One aliquot of  BALF (1 ml) was directly mixed with iced methanol (2 ml, for 
1:2, vol/vol) before storing at –80°C. The other aliquots were directly stored at –80°C. The stored aliquots 
were later shipped to Brigham and Women’s Hospital for analyses.
Lipid extraction. Aliquots of BALF with methanol (1:2, vol/vol) were brought to dryness in vacuo using 
a BÜCHI Rotavapor R-200/205. The samples were resuspended with methanol (500 μl) and distilled/deion-
ized water (10 ml) followed by extraction using C18 SepPak cartidges (Waters) as previously described (13). 
The methyl formate fraction was brought to dryness under a gentle stream of nitrogen and each sample was 
resuspended in 1 ml of methanol and stored at –80°C until LXA4 and 15-epi-LXA4 ELISAs were performed.
Protein assay. The Pierce BCA Protein Assay Kit (Thermo Fisher) was used for BALF protein determi-
nation. Samples with less than 25 μg of  protein were excluded from further analysis (n = 3; 1 NSA, 2 SA).
ELISA. LXA4 and 15-epi-LXA4 levels in the BALF were measured by ELISA (Neogen). Extracted 
BALF samples stored in methanol were brought to dryness under a gentle stream of  nitrogen and resuspend-
ed in ELISA buffer. SAA and ANXA1 levels were measured by ELISA (commercial kits from Abazyme 
and Cloud-Clone, respectively) in aliquots of  BALF stored in the absence of  methanol. LXA4, 15-epi-LXA4, 
SAA, and ANXA1 levels were normalized to the total protein content of  the BALF. Some subjects had an 
SAA level below the limit of  detection and these samples were assigned a value of  0 pg/μg protein for analy-
sis. The median values for LXA4 and SAA were used to segregate subjects into high and low subgroups.
Flow cytometry. BAL cell pellets were available from a subgroup of subjects. For ex vivo staining, BALF 
cells were blocked with mouse serum (Sigma-Aldrich) in PBS for 30 minutes at 4°C. The cells were then 
incubated with Viability Dye eFluorR660 (eBioscience) as per the manufacturer’s instructions followed by 30 
minutes of incubation with the following antibodies against human proteins: anti-ALX-PerCP (clone 304405, 
R&D Systems); anti–HLA-DR (MHC class II)-allophycocyanin-Cy7 (APC-Cy7) (clone L243, BD Bioscienc-
es); and anti-CD206 (macrophage mannose receptor)-phycoerythrin (PE) (clone 19.2, eBioscience) or with 
directly conjugated unrelated antibodies of the same isotype (BD Biosciences) at 4°C. Data were acquired on 
a Canto II flow cytometer (Becton Dickinson) and analyzed using FlowJo software version 10.1 (Tree Star). 
Macrophages were identified as single cells (by doublet exclusion), viable (Viability Dye eFluorR660 negative), 
CD206+ cells. The MFI of ALX, MHC class II, and CD206 was assessed on macrophages and normalized 
with the MFI of the isotype control antibody (MFI cell surface marker/MFI isotype control = MFI index).
In vitro A549 cell culture. A549 cells transfected to stably express the human ALX receptor were used (as 
in ref. 18). A549hALX cells were seeded into a 48-well plate (5 × 104 cells/well) and cultured in RPMI 1640 
(Lonza) supplemented with 2 mM L-glutamine, 10% heat-inactivated fetal calf  serum (Gibco), penicillin 
(100 IU/ml), and streptomycin (100 μg/ml) at 37°C in 5% CO2 until confluent. When confluent, A549
hALX 
cells were cultured with serum-free media for 16 hours and then exposed to BALF (100 μl) and serum-free 
RPMI media (100 μl, 1:1 vol/vol) for 24 hours (37°C, 5% CO2). In select experiments, recombinant human 
SAA (0–10 ng/ml, Peprotech), 15-epi-LXA4 (100 nM, Cayman Chemical), or vehicle control was added. 
At the end of  the incubations, supernatants were collected on ice and stored at –80°C. IL-8 levels in the 
supernatants were measured by ELISA (R&D Systems). If  there was no increase in IL-8 production after 
exposure to BALF, the samples were assigned a value of  zero (Figure 6C).
Statistics. In figures, data are expressed either individually with indication of  the median value or as 
mean ± SEM; in tables, data are expressed as mean ± SD. For violin plots in Figure 4, bin sizes and widths 
were determined for each variable automatically in SPSS based on the underlying data distribution. Sta-
tistical significance of  differences was assessed by 2-tailed Student’s t test, 1-way ANOVA, Kruskal-Wallis 
test (when normality assumptions were not met), or χ2 test as noted using SPSS version 23.0 (IBM). Post 
hoc Tukey’s test (for ANOVA analyses) and Dunn’s test (for Kruskal-Wallis analyses) were used to correct 
for multiple comparisons. Correlations were evaluated by Pearson’s correlation coefficient (r) and linear 
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or nonlinear (for graphs with log axes) regression lines are shown. Correlation analyses included samples 
with a value of  0 for statistical analysis, but data points with a value of  0 were excluded for regression line 
analyses of  detectable ALX ligands. A P value less than 0.05 was considered significant and the reported P 
values were adjusted for multiple comparisons.
Study approval. Written informed consent was obtained after institutional review board approval at each 
of  the seven sites.
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